Florian Stéphan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Florian Stéphan has a total of 97 co-authors. Here are the top co-authors by number of shared publications:
- Wissam El-Hage
INSERM, Imaging Brain & Neuropsychiatry iBraiN U1253, Université de Tours
5 shared publications - Antoine Yrondi
Department of Psychiatry and Medical Psychology, Expert Center for Treatment-Resistant Depression and Bipolar Disorder FondaMental Foundation, Toulouse University Hospital (CHU de Toulouse), Purpan Hospital, Toulouse NeuroImaging Center (ToNIC), University of Toulouse, Inserm U1214, UPS, Toulouse, France – FondaMental Foundation, Créteil, France
4 shared publications - Bruno Aouizerate
Fondation FondaMental, Créteil, France; Centre Hospitalier Charles Perrens, Pôle PGU, Laboratoire de psychologie LabPsy UR4139, Université de Bordeaux, Bordeaux, France
3 shared publications - Djamila Bennabi
Fondation FondaMental, 94000 Créteil, France
3 shared publications - Emmanuel Haffen
Université Marie et Louis Pasteur, INSERM, UMR 1322 LINC, Besançon, France
3 shared publications - Guillaume Vaiva
CHRU Lille, Centre Hospitalier Universitaire de Lille, Lille, France
3 shared publications
Latest Publications
- Open Access
- 8 July 2026
- Published by JMIR Publications Inc. in JMIR Preprints
Suicidal Ideation Trajectories After Alerts: A retrospective cohort using Digital Measurement-Based Care for Mood Disorders (Preprint)
BACKGROUND Measurement-based care improves depression outcomes, yet implementation remains uncommon. Digital remote patient monitoring (RPM) tools collecting patient-reported outcomes (PROs) with automated alerts are increasingly deployed, but the respective contributions of algorithmic detection and clinician response remain unclear. OBJECTIVE To describe real-world use of a CE-marked digital RPM device for mood disorders and characterize symptom trajectories around algorithmic alerts, distinguishing alerts overall from those followed by clinician response. METHODS Multicenter retrospective cohort study using post-market clinical follow-up data from October 31, 2025, to May 4, 2026, implying thirty-four French psychiatric centers using a Class IIa CE-marked RPM device. We included all consecutive adults (≥18 years) treated for major depressive episode or manic episode, who completed at least one weekly questionnaire and did not opt out of research use of their data. The questionnaires consisted in weekly electronic PROs collection (PHQ-9, suicidal ideation item, adapted GAD-2, medication adherence) with threshold-based alerts routed to clinical teams. Alerts were classified as followed or not by documented clinician response. Outcomes included engagement and operational metrics (completion rate, patient response time, alert processing time, response conversion rate) and exploratory pre/post-alert trajectories for suicidal ideation, anxiety, and depression, analyzed using segmented interrupted time-series regression with Newey-West correction at both the alert and response-bearing alert levels. RESULTS Among 111 patients (median [IQR] age, 41 [31-54] years; 76% female), 84% were treated for depressive disorders, and 16% for bipolar disorder. Overall, 92% of questionnaires were completed, with completion rates exceeding 80% through month 5. Median patient response time was 17 hours, median clinician response time after alerts was 50 hours, and 69% of alerts were followed by a documented response. Response-bearing alerts were associated with significant slope inflections for suicidal ideation (−0.007/day; P=0.01) and anxiety (−0.004 per day; P<0.001), with nonsignificant trend for depression. Across all alerts, no inflection was observed for suicidal ideation, whereas anxiety showed a significant inflection and depression a level shift without slope change. CONCLUSIONS In this real-world cohort, symptom trajectory changes were most evident when alerts were followed by clinician response. These findings support further evaluation of closed-loop RPM in randomized trials. CLINICALTRIAL The study was conducted under the French Reference Methodology MR-004 of the Commission Nationale de l'Informatique et des Libertés (CNIL) (research not involving human subjects, in-house studies on health data).
- 8 July 2026
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessSuicidal Ideation Trajectories After Alerts: A retrospective cohort using Digital Measurement-Based Care for Mood Disorders (Preprint)
BACKGROUND Measurement-based care improves depression outcomes, yet implementation remains uncommon. Digital remote patient monitoring (RPM) tools collecting patient-reported outcomes (PROs) with automated alerts are increasingly deployed, but the respective contributions of algorithmic detection and clinician response remain unclear. OBJECTIVE To describe real-world use of a CE-marked digital RPM device for mood disorders and characterize symptom trajectories around algorithmic alerts, distinguishing alerts overall from those followed by clinician response. METHODS Multicenter retrospective cohort study using post-market clinical follow-up data from October 31, 2025, to May 4, 2026, implying thirty-four French psychiatric centers using a Class IIa CE-marked RPM device. We included all consecutive adults (≥18 years) treated for major depressive episode or manic episode, who completed at least one weekly questionnaire and did not opt out of research use of their data. The questionnaires consisted in weekly electronic PROs collection (PHQ-9, suicidal ideation item, adapted GAD-2, medication adherence) with threshold-based alerts routed to clinical teams. Alerts were classified as followed or not by documented clinician response. Outcomes included engagement and operational metrics (completion rate, patient response time, alert processing time, response conversion rate) and exploratory pre/post-alert trajectories for suicidal ideation, anxiety, and depression, analyzed using segmented interrupted time-series regression with Newey-West correction at both the alert and response-bearing alert levels. RESULTS Among 111 patients (median [IQR] age, 41 [31-54] years; 76% female), 84% were treated for depressive disorders, and 16% for bipolar disorder. Overall, 92% of questionnaires were completed, with completion rates exceeding 80% through month 5. Median patient response time was 17 hours, median clinician response time after alerts was 50 hours, and 69% of alerts were followed by a documented response. Response-bearing alerts were associated with significant slope inflections for suicidal ideation (−0.007/day; P=0.01) and anxiety (−0.004 per day; P<0.001), with nonsignificant trend for depression. Across all alerts, no inflection was observed for suicidal ideation, whereas anxiety showed a significant inflection and depression a level shift without slope change. CONCLUSIONS In this real-world cohort, symptom trajectory changes were most evident when alerts were followed by clinician response. These findings support further evaluation of closed-loop RPM in randomized trials. CLINICALTRIAL The study was conducted under the French Reference Methodology MR-004 of the Commission Nationale de l'Informatique et des Libertés (CNIL) (research not involving human subjects, in-house studies on health data).
- Open Access
- 18 May 2026
- Published by Medical Journals Sweden AB in Acta Dermato-Venereologica
- Vol. 106
Perceived Stress, Illness and Stigma in Patients with Alopecia Areata
Alopecia areata is a nonscarring autoimmune hair loss disorder. Little is known about patients’ perceptions of their condition. This French cross-sectional online study primarily aimed to assess patients’ perception of stress as a causal factor, with secondary objectives examining illness perception and stigma. Adults aged ≥18 years with a confirmed alopecia areata diagnosis were included.The primary outcome was patients” attribution of stress as a cause of alopecia areata, while secondary outcomes included IPQ-R and PUSHD scores. Among 96 participants, there was a strong female predominance (15.6 : 1) and a high proportion of alopecia totalis (65%). Stress was identified as a cause by 52 patients (54%), and this belief was shared by their dermatologist in 18 cases (35%). Patients reported significant emotional consequences, major life impact and a chronic course. Those attributing alopecia areatato stress showed higher perceived personal control (15.3±4.9 vs. 12.7±4.3; p=0.006). The mean PUSHD score was 18. Poorer perceived consequences and stronger emotional representations correlated with greater stigma (ρ=0.56; ρ=0.59; p<0.05), while lower disease understanding correlated with higher stigma (ρ=−0.34; p<0.05). Integrating educational programmes into routine care may enhance patients with alopecia areata understanding and coping.
- 18 May 2026
- Published by Medical Journals Sweden AB in Acta Dermato-Venereologica
- Vol. 106
Open AccessPerceived Stress, Illness and Stigma in Patients with Alopecia Areata
Alopecia areata is a nonscarring autoimmune hair loss disorder. Little is known about patients’ perceptions of their condition. This French cross-sectional online study primarily aimed to assess patients’ perception of stress as a causal factor, with secondary objectives examining illness perception and stigma. Adults aged ≥18 years with a confirmed alopecia areata diagnosis were included.The primary outcome was patients” attribution of stress as a cause of alopecia areata, while secondary outcomes included IPQ-R and PUSHD scores. Among 96 participants, there was a strong female predominance (15.6 : 1) and a high proportion of alopecia totalis (65%). Stress was identified as a cause by 52 patients (54%), and this belief was shared by their dermatologist in 18 cases (35%). Patients reported significant emotional consequences, major life impact and a chronic course. Those attributing alopecia areatato stress showed higher perceived personal control (15.3±4.9 vs. 12.7±4.3; p=0.006). The mean PUSHD score was 18. Poorer perceived consequences and stronger emotional representations correlated with greater stigma (ρ=0.56; ρ=0.59; p<0.05), while lower disease understanding correlated with higher stigma (ρ=−0.34; p<0.05). Integrating educational programmes into routine care may enhance patients with alopecia areata understanding and coping.
- Open Access
- 23 August 2025
- Published by Elsevier in L'Encéphale
- Vol. 52 (2) , 208-211
Aide à la prescription des psychotropes par télé-expertise
- 23 August 2025
- Published by Elsevier in L'Encéphale
- Vol. 52 (2) , 208-211
Open AccessAide à la prescription des psychotropes par télé-expertise
- Open Access
- 26 May 2025
- Published by EDP Sciences in médecine/sciences
- Vol. 41 (5) , 469-476
Les anomalies sensorielles
Les anomalies sensorielles, transdiagnostiques dans les troubles de l’humeur, du spectre de l’autisme ou de la schizophrénie, affectent les interactions sociales, le comportement et les fonctions cognitives. Touchant divers canaux sensoriels (auditifs, visuels, olfactifs), elles apparaissent comme centrales dans ces troubles. Les modèles animaux révèlent des déséquilibres du système glutamate-GABA, associés à des altérations cognitives et à une dysrégulation de la balance excitation/inhibition, et facilitent le transfert des découvertes à l’humain grâce à l’applicabilité des paradigmes. L’étude de la cohorte pluridisciplinaire French Minds, via des outils cliniques, tels que l’imagerie par résonance magnétique fonctionnelle et l’électroencéphalogramme, explore ces dimensions pour redéfinir les approches diagnostiques et thérapeutiques de ces troubles.
- 26 May 2025
- Published by EDP Sciences in médecine/sciences
- Vol. 41 (5) , 469-476
Open AccessLes anomalies sensorielles
Les anomalies sensorielles, transdiagnostiques dans les troubles de l’humeur, du spectre de l’autisme ou de la schizophrénie, affectent les interactions sociales, le comportement et les fonctions cognitives. Touchant divers canaux sensoriels (auditifs, visuels, olfactifs), elles apparaissent comme centrales dans ces troubles. Les modèles animaux révèlent des déséquilibres du système glutamate-GABA, associés à des altérations cognitives et à une dysrégulation de la balance excitation/inhibition, et facilitent le transfert des découvertes à l’humain grâce à l’applicabilité des paradigmes. L’étude de la cohorte pluridisciplinaire French Minds, via des outils cliniques, tels que l’imagerie par résonance magnétique fonctionnelle et l’électroencéphalogramme, explore ces dimensions pour redéfinir les approches diagnostiques et thérapeutiques de ces troubles.
- Open Access
- 24 July 2023
- Published by MDPI AG in Brain Sciences
- Vol. 13 (7) , 1120
Evolution of Cognitive Impairments in Treatment-Resistant Depression: Results from the Longitudinal French Centers of Expertise for Treatment-Resistant Depression (FACE-DR) Cohort
Previous studies set out profound cognitive impairments in subjects with treatment-resistant depression (TRD). However, little is known about the course of such alterations depending on levels of improvement in those patients followed longitudinally. The main objective of this study was to describe the course of cognitive impairments in responder versus non-responder TRD patients at one-year follow-up. The second aim was to evaluate the predictive aspect of cognitive impairments to treatment resistance in patients suffering from TRD. We included 131 patients from a longitudinal cohort (FACE-DR) of the French Network of Expert TRD Centers. They undertook comprehensive sociodemographic, clinical, global functioning, and neuropsychological testing (TMT, Baddeley task, verbal fluencies, WAIS-4 subtests, D2 and RLRI-16) at baseline (V0) and one-year follow-up (V1). Most patients (n = 83; 63.36%) did not respond (47 women, 49.47 ± 12.64 years old), while one-third of patients responded (n = 48, 30 women, 54.06 ± 12.03 years old). We compared the cognitive performances of participants to average theoretical performances in the general population. In addition, we compared the cognitive performances of patients between V1 and V0 and responder versus non-responder patients at V1. We observed cognitive impairments during the episode and after a therapeutic response. Overall, each of them tended to show an increase in their cognitive scores. Improvement was more prominent in responders at V1 compared to their non-responder counterparts. They experienced a more marked improvement in code, digit span, arithmetic, similarities, and D2 tasks. Patients suffering from TRD have significant cognitive impairments that persist but alleviate after therapeutic response. Cognitive remediation should be proposed after therapeutic response to improve efficiency and increase the daily functioning.
- 24 July 2023
- Published by MDPI AG in Brain Sciences
- Vol. 13 (7) , 1120
Open AccessEvolution of Cognitive Impairments in Treatment-Resistant Depression: Results from the Longitudinal French Centers of Expertise for Treatment-Resistant Depression (FACE-DR) Cohort
Previous studies set out profound cognitive impairments in subjects with treatment-resistant depression (TRD). However, little is known about the course of such alterations depending on levels of improvement in those patients followed longitudinally. The main objective of this study was to describe the course of cognitive impairments in responder versus non-responder TRD patients at one-year follow-up. The second aim was to evaluate the predictive aspect of cognitive impairments to treatment resistance in patients suffering from TRD. We included 131 patients from a longitudinal cohort (FACE-DR) of the French Network of Expert TRD Centers. They undertook comprehensive sociodemographic, clinical, global functioning, and neuropsychological testing (TMT, Baddeley task, verbal fluencies, WAIS-4 subtests, D2 and RLRI-16) at baseline (V0) and one-year follow-up (V1). Most patients (n = 83; 63.36%) did not respond (47 women, 49.47 ± 12.64 years old), while one-third of patients responded (n = 48, 30 women, 54.06 ± 12.03 years old). We compared the cognitive performances of participants to average theoretical performances in the general population. In addition, we compared the cognitive performances of patients between V1 and V0 and responder versus non-responder patients at V1. We observed cognitive impairments during the episode and after a therapeutic response. Overall, each of them tended to show an increase in their cognitive scores. Improvement was more prominent in responders at V1 compared to their non-responder counterparts. They experienced a more marked improvement in code, digit span, arithmetic, similarities, and D2 tasks. Patients suffering from TRD have significant cognitive impairments that persist but alleviate after therapeutic response. Cognitive remediation should be proposed after therapeutic response to improve efficiency and increase the daily functioning.
- 6 June 2022
- Published by Elsevier in The European Journal of Psychiatry
- Vol. 36 (3) , 143-151
Inflammatory biomarkers associated with depression, anxiety, and/or fatigue in primary Sjögren's syndrome – a systematic review
- 6 June 2022
- Published by Elsevier in The European Journal of Psychiatry
- Vol. 36 (3) , 143-151
Inflammatory biomarkers associated with depression, anxiety, and/or fatigue in primary Sjögren's syndrome – a systematic review
- Open Access
- 10 December 2020
- Published by MDPI AG in Brain Sciences
- Vol. 10 (12) , 962
Treatment-Resistant Depression in a Real-World Setting: First Interim Analysis of Characteristics, Healthcare Resource Use, and Utility Values of the FondaMental Cohort
Background: Major depressive disorder (MDD) is among the most common psychiatric disorders. One-third of patients are usually unresponsive to several lines of treatment. This study aimed to describe the FondaMental French cohort of patients with treatment-resistant depression (TRD) and to estimate utility and healthcare resource use outcomes. Methods: Patients with TRD were evaluated prospectively over four years (baseline, 6, 12, 18, 24, 36 and 48 months) in a real-world clinical setting. Interim analyses focused on the first two consecutive years. Four MDD-related states (major depressive episode (MDE), response, remission, recovery) were defined based on the MADRS (Montgomery–Åsberg depression rating scale) and other clinical events. Health status was assessed with the EuroQol 5 Dimensions 5 Level (EQ-5D-5L) questionnaire. Utility values were estimated as preference measures that the patients assigned to their overall health status. Results: This study was based on 252 patients with TRD. The mean utility value by health state was 0.41, 0.63, 0.80, and 0.90, for MDE, response, remission, and recovery, respectively. At baseline, 59% of patients had an MADRS score of at least 28. Their baseline average utility value was lower compared to the other patients (0.43 versus 0.58, p < 0.001). This significant difference persisted at the following visits. The rate of patients in MDEs having at least one hospitalisation for depression or other reasons than depression was generally higher than that in the other health states. Conclusion: This study documented patterns in healthcare resource consumption, quality of life, and other characteristics in patients with TRD, both globally and by health state and depression severity.
- 10 December 2020
- Published by MDPI AG in Brain Sciences
- Vol. 10 (12) , 962
Open AccessTreatment-Resistant Depression in a Real-World Setting: First Interim Analysis of Characteristics, Healthcare Resource Use, and Utility Values of the FondaMental Cohort
Background: Major depressive disorder (MDD) is among the most common psychiatric disorders. One-third of patients are usually unresponsive to several lines of treatment. This study aimed to describe the FondaMental French cohort of patients with treatment-resistant depression (TRD) and to estimate utility and healthcare resource use outcomes. Methods: Patients with TRD were evaluated prospectively over four years (baseline, 6, 12, 18, 24, 36 and 48 months) in a real-world clinical setting. Interim analyses focused on the first two consecutive years. Four MDD-related states (major depressive episode (MDE), response, remission, recovery) were defined based on the MADRS (Montgomery–Åsberg depression rating scale) and other clinical events. Health status was assessed with the EuroQol 5 Dimensions 5 Level (EQ-5D-5L) questionnaire. Utility values were estimated as preference measures that the patients assigned to their overall health status. Results: This study was based on 252 patients with TRD. The mean utility value by health state was 0.41, 0.63, 0.80, and 0.90, for MDE, response, remission, and recovery, respectively. At baseline, 59% of patients had an MADRS score of at least 28. Their baseline average utility value was lower compared to the other patients (0.43 versus 0.58, p < 0.001). This significant difference persisted at the following visits. The rate of patients in MDEs having at least one hospitalisation for depression or other reasons than depression was generally higher than that in the other health states. Conclusion: This study documented patterns in healthcare resource consumption, quality of life, and other characteristics in patients with TRD, both globally and by health state and depression severity.
- Open Access
- 30 January 2019
- Published by Springer Nature in BMC Psychiatry
- Vol. 19 (1) , 1-9
Clinical guidelines for the management of depression with specific comorbid psychiatric conditions French recommendations from experts (the French Association for Biological Psychiatry and Neuropsychopharmacology and the fondation FondaMental)
Recommendations for pharmacological treatments of major depression with specific comorbid psychiatric conditions are lacking. The French Association for Biological Psychiatry and Neuropsychopharmacology and the fondation FondaMental developed expert consensus guidelines for the management of depression based on the RAND/UCLA Appropriatneness Method. Recommendations for lines of treatment are provided by the scientific committee after data analysis and interpretation of the results of a survey of 36 psychiatrist experts in the field of major depression and its treatments. The expert guidelines combine scientific evidence and expert clinician’s opinion to produce recommendations for major depression with comorbid anxiety disorders, personality disorders or substance use disorders and in geriatric depression. These guidelines provide direction addressing common clinical dilemmas that arise in the pharmacologic treatment of major depression with comorbid psychiatric conditions.
- 30 January 2019
- Published by Springer Nature in BMC Psychiatry
- Vol. 19 (1) , 1-9
Open AccessClinical guidelines for the management of depression with specific comorbid psychiatric conditions French recommendations from experts (the French Association for Biological Psychiatry and Neuropsychopharmacology and the fondation FondaMental)
Recommendations for pharmacological treatments of major depression with specific comorbid psychiatric conditions are lacking. The French Association for Biological Psychiatry and Neuropsychopharmacology and the fondation FondaMental developed expert consensus guidelines for the management of depression based on the RAND/UCLA Appropriatneness Method. Recommendations for lines of treatment are provided by the scientific committee after data analysis and interpretation of the results of a survey of 36 psychiatrist experts in the field of major depression and its treatments. The expert guidelines combine scientific evidence and expert clinician’s opinion to produce recommendations for major depression with comorbid anxiety disorders, personality disorders or substance use disorders and in geriatric depression. These guidelines provide direction addressing common clinical dilemmas that arise in the pharmacologic treatment of major depression with comorbid psychiatric conditions.